Complete Reversal of Nephrotic Syndrome Secondary to Amyloidosis with Use of Infliximab in a Patient with Inflammatory Bowel Disease and Ankylosing Spondylitis

• Published in: Renal failure Vol. 33; no. 5; pp. 531 - 533
• Main Authors: Akdo an, Mehmet Fatih, Gücün, Murat, Denizli, Naz m, Güney, Murat, Akdag, brahim, Özcan, Tevhide Bilgen, Duranay, Murat
• Format: Journal Article
• Language: English
• Published: England Informa Healthcare 01.06.2011; Taylor & Francis
• Subjects: Adult; amyloidosis; Amyloidosis - complications; ankylosing spondylitis; Antibodies, Monoclonal - therapeutic use; Antirheumatic Agents - therapeutic use; Colitis, Ulcerative - complications; Female; Humans; Infliximab; Nephrotic Syndrome - drug therapy; Nephrotic Syndrome - etiology; Spondylitis, Ankylosing - complications; Spondylitis, Ankylosing - drug therapy; Ulcerative colitis
• ISSN: 0886-022X; 1525-6049
• DOI: 10.3109/0886022X.2011.577543

A 30-year-old woman was diagnosed with ulcerative colitis in January 2006. One year later, she presented because of severe back pain and was diagnosed with ankylosing spondylitis (AS). In February 2008, the patient, while still under standard treatment for ulcerative colitis and AS, was admitted because of massive proteinuria and related symptoms. Nephrotic syndrome was observed and renal biopsy revealed amyloid deposits. After treatment with infliximab, nephrotic syndrome disappeared. We aim to present a case of secondary amyloidosis complicating ulcerative colitis and associated spondyloarthropathy.